Sitravatinib

立即咨询

Sitravatinib

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1123837-84-2

包装与价格：

包装	价格(元)
5mg	电议
10mg	电议
50mg	电议
100mg	电议
200mg	电议

产品介绍

Sitravatinib (MGCD516) 是一种口服生物利用度受体酪氨酸激酶 (RTK) 抑制剂，IC50 为 1.5 nM、2 nM、2 nM、5 nM、6 nM、6 nM、8 nM、0.5 nM、29 nM、5 nM 和 9 nM 分别代表 Axl、MER、VEGFR3、VEGFR2、VEGFR1、KIT、FLT3、DDR2、DDR1、TRKA、TRKB 。

Cas No.	1123837-84-2
别名	MGCD516; MG-516
Canonical SMILES	O=C(C1(C(NC2=CC=C(F)C=C2)=O)CC1)NC3=CC=C(OC4=C5C(C=C(C6=NC=C(CNCCOC)C=C6)S5)=NC=C4)C(F)=C3
分子式	C₃₃H₂₉F₂N₅O₄S
分子量	629.68
溶解度	DMSO : ≥ 32 mg/mL (50.82 mM)
储存条件	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request
产品描述	Sitravatinib is a novel small molecule inhibitor targeting multiple RTKs involved in driving sarcoma cell growth with IC50 of 3980 nmol/Lin vitro: MGCD516 is superior to other multi-kinase inhibitors in inhibiting cell proliferation, RTK phosphorylation, and phosphorylation of downstream effectors. MGCD516 is unique in a way that it has broad spectrum activity against many RTKs including c-Met, c-Kit, Axl, PDGFR, and Eph receptors that are known to play a role in driving sarcoma cell growthIn vivo: MGCD516 induces significant tumor growth suppression than imatinib and crizotinib. References: [1]. Patwardhan PP et al. Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma. Oncotarget, 2016 Jan 26;7(4):4093-109.